Search
fremanezumab (Ajovy)
Indications:
- prevention of chronic migraine [1,2] (FDA-approved 9/18 [3])
- benefit for patients with comorbid depression &/or anxiety [4]
* clinical utility not established [1]
* 1.3-1.5-day reduction in mean number of monthly migraine days [2]
Dosage:
- 675 mg SQ at baseline & 225 mg every 4 weeks
Adverse effects:
- injection site reactions (common)
Mechanism of action:
- humanized monoclonal antibody targeting CGRP (calcitonin gene-related peptide)
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
neurologic agent
References
- Silberstein SD, Dodick DW, Bigal M et al
Fremanezumab for the Preventive Treatment of Chronic Migraine.
N Engl J Med 2017; 377:2113-2122. Nov 30, 2017
PMID: 29171818
http://www.nejm.org/doi/full/10.1056/NEJMoa1709038
- Dodick DW, Silberstein SD, Bigal M et al
Effect of Fremanezumab Compared With Placebo for Prevention
of Episodic Migraine. A Randomized Clinical Trial.
JAMA. 2018;319(19):1999-2008. May 15, 2018
PMID: 29800211
https://jamanetwork.com/journals/jama/fullarticle/2681193
- NEJM JWatch Editors
New Migraine Prevention Treatment Approved
Physician's First Watch, Sept 17, 2018
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- Brauser D
FDA Approves Fremanezumab (Ajovy) for Migraine Prevention.
Medscape - Sep 17, 2018
https://www.medscape.com/viewarticle/902071
- Monaco K
Migraine Drug Shows Benefit for Those With Comorbid Depression, Anxiety.
MedPage Today November 1, 2021
https://www.medpagetoday.com/meetingcoverage/psychcongress/95365